News

13
Jul

PRESS RELEASE: TECHLAB® Receives FDA 510(k) Clearance To Market TRI-COMBO PARASITE SCREEN™ To Aid Clinicians In The Diagnosis Of Giardiasis, Cryptosporidiosis, And Amebiasis

Read the full release here. BLACKSBURG, Va., July 13, 2017 /PRNewswire/ -- TECHLAB®, Inc., a leading developer and manufacturer of rapid non-invasive diagnostic tests for gastrointestinal diseases, today announced that it received U.S. Food and Drug Administration (FDA) clearance for the TRI-COMBO PARASITE SCREEN™ test. The TRI-COMBO PARASITE SCREEN ™ test provides a complete analysis for Giardia, Cryptosporidium, and Entamoeba ...

13
Jun

PRESS RELEASE: TECHLAB® Receives FDA 510(k) Clearance To Market E. HISTOLYTICA QUIK CHEK™ To Aid Clinicians In The Diagnosis Of Amebiasis Caused By The E. Histolytica Parasite

Read the full release here. BLACKSBURG, Va., June 13, 2017 /PRNewswire/ -- TECHLAB,® Inc., a leading developer and manufacturer of rapid, non-invasive diagnostic tests for gastrointestinal disease, today announced that it received U.S. Food and Drug Administration (FDA) clearance for E. HISTOLYTICA QUIK CHEK™ test.  E. HISTOLYTICA QUIK CHEK™ test is the only rapid diagnostic test that ...

30
May

PRESS RELEASE: TECHLAB® To Showcase Its C. DIFF QUIK CHEK COMPLETE® At 2017 American Society For Microbiology Microbe Meeting

Read the full release here. BLACKSBURG, Va., May 30, 2017 /PRNewswire/ -- TECHLAB® Inc., a leading developer and manufacturer of rapid, non-invasive diagnostic tests for gastrointestinal disease, today announced that it will be showcasing C. DIFF QUIK CHEK COMPLETE® at the American Society for Microbiology Microbe 2017 meeting in New Orleans, 

19
Sep

PRESS RELEASE: Pharos Capital Acquires TechLab, Leading Developer of Gastrointestinal Disease Diagnostics

Read the full release here. DALLAS & NASHVILLE, Tenn.--(BUSINESS WIRE)--Pharos Capital Group, LLC (“Pharos”), a private equity firm based in Dallas and Nashville, announced it has acquired a controlling position in TechLab, Inc. (“TechLab” or “the Company”), a developer and manufacturer of rapid, non-invasive diagnostic tests for gastrointestinal disease. Pharos is acquiring its stake from Alere, Inc. (NYSE:ALR) ...

12